BC Extra | Apr 24, 2019
Company News

Biogen reiterates late-stage M&A priority as it calls off planned aducanumab trial

As it contemplates exiting β-amyloid programs, Biogen is prioritizing late-stage M&A to shore up its pipeline and preparing to deliver near-term Phase II readouts from a stable of other non-Alzheimer's disease candidates. The bellwether also...
BC Innovations | Feb 28, 2019
Tools & Techniques

Synuclein PET project

As the Parkinson’s field starts to solve the problem of how to detect toxic α-synuclein in the brain, it’s closing in on imaging agents that could de-risk clinical trials. Phase I data expected this year...
BC Week In Review | Nov 9, 2018
Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BC Extra | Nov 2, 2018
Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
BioCentury | May 11, 2018
Emerging Company Profile

Enterin the gut

Enterin Inc. has a new twist on the longstanding Parkinson’s disease target alpha synuclein. The biotech is inhibiting the protein’s accumulation in intestinal nerves rather than in the brain, with the goal of treating constipation...
BC Innovations | Jun 20, 2017
Distillery Therapeutics

Cancer

INDICATION: Melanoma Patient sample and cell culture studies suggest α-synuclein inhibitors could help treat melanoma. In patients, tumor levels of α-synuclein were higher in cases of more advanced disease, including metastatic growth phase and vertical...
BC Innovations | Jul 21, 2016
Distillery Therapeutics

Therapeutics: α-synuclein (SNCA)

Neurology INDICATION: Stroke Mouse studies suggest α-synuclein inhibitors could help treat stroke. In a mouse model of stroke caused by transient middle cerebral artery occlusion, systemic knockout of α-synuclein decreased infarct volume and increased motor...
BC Innovations | May 12, 2016
Translation in Brief

PET projects

Recent high-profile failures in clinical trials for Alzheimer's disease (AD) have underscored the role that imaging agents could play in identifying the right trial populations and tracking their responses. AC Immune S.A. and Biogen Inc....
Items per page:
1 - 9 of 9